Syndax Pharmaceuticals, Inc. (SNDX) Stock Score, Valuation & Financial Research

Syndax Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SNDX

Syndax Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 17.37. These figures are a research snapshot, not a buy or sell recommendation.

What Syndax Pharmaceuticals, Inc. does

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of its FDA-approved oncology products, Revuforj and Niktimvo, as well as through collaboration, milestone, license, and royalty agreements with strategic partners.

Products and services

  • The company's portfolio includes Revuforj (revumenib), a menin inhibitor, and Niktimvo (axatilimab-csfr), a monoclonal antibody targeting the CSF-1 receptor, both indicated for specific cancer treatments.

Brands and product families

  • Revuforj — FDA-approved menin inhibitor for the treatment of certain leukemias. Source
  • Niktimvo — FDA-approved monoclonal antibody for the treatment of chronic graft-versus-host disease. Source

Annual revenue by business

  • Net Product Revenues: USD 124,844,000 · 72.44% calculated revenue share (period 2025-12-31) Source
  • Collaboration revenue: USD 42,367,000 · 24.58% calculated revenue share (period 2025-12-31) Source
  • Milestone Revenue: USD 5,141,000 · 2.98% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Specialty pharmacies; Hospitals and oncology clinics.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of drug substance and drug product; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Incyte Corporation — A strategic collaboration for the development and commercialization of axatilimab (Niktimvo) in chronic graft-versus-host disease. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies developing oncology therapies — The company competes with various pharmaceutical and biotechnology firms developing therapies for leukemia and graft-versus-host disease. Source

Business strengths to evaluate

  • FDA-approved commercial product portfolio Source
  • Robust clinical development pipeline Source

Business risks and research considerations

  • History of operating losses and accumulated deficit Source
  • Dependence on third-party manufacturers and suppliers Source

Sources: Company research source · Net Product Revenues · Revuforj

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SNDX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 17.37
Market capitalization:
1.54B (currency not supplied)
Revenue:
USD 252M
Net income:
USD -220.77M
Free cash flow:
USD -323.17M
Cash:
USD 336.48M
Total debt:
USD 589.38M
EPS:
USD -2.52

What stands out

  • Reported year-over-year revenue growth is +46.2%.
  • Free cash flow is USD -323.17M, negative for the stored period.
  • The balance sheet shows USD 336.48M of cash versus USD 589.38M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -128.2% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -87.6% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 252.91M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SNDX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can SNDX sustain its current revenue growth while also converting that growth into durable profit and free cash flow?
  • How long can SNDX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does SNDX's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for SNDX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SNDX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research SNDX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.